Email Us:
To contact Trxade, please complete the form below and a team member will reply as soon as possible.
FDA Stay Informed RSS
- Newly Added Guidance Documents December 6, 2019Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.FDA
FiercePharma News RSS
- Acadia's Nuplazid could hit blockbuster heights after strong psychosis data: analyst December 5, 2019When Acadia trumpeted news that it would end a late-stage trial for its Nuplazid in dementia-related psychosis (DRP) early, it represented a big win for a drugmaker still stinging from a major schizophrenia flop. Now, data from that trial are giving some analysts hope that Nuplazid could hit blockbuster heights—with or without schizophrenia.Kyle Blankenship